Clinical trial
COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2…
NCT04452318 · Regeneron Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT04452318 |
|---|---|
| Title | COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay |
| Official title | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 |
| Lead sponsor | Regeneron Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Healthy Participants |
| Intervention type | Drug |
| Interventions | REGN10933 + REGN10987, Placebo |
| Enrollment | 3,303 |
| Start date | Jul 13, 2020 |
| Primary completion | Oct 4, 2021 |
| Completion | Oct 4, 2021 |
| First posted | Jun 30, 2020 |
| Last update posted | May 15, 2023 |
| Countries | Moldova, Romania, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: